Nifedipine reverses the abnormalities in lCa241i and proliferation of B cells from dialysis patients. Both animals and patients with chronic renal failure have impaired B cell function due, in part, to elevated levels of cytosolic calcium ([Ca2ji 0.38 x iO cpm) and smaller inhibition of B cell proliferation by PTH compared to those treated with nifedipine. The values in the patients treated with nifedipine were still modestly but significantly different than in normal subjects. The serum IgG levels of the patients without nifedipine therapy (1210 71 mg/dl) were significantly lower than those of the patients treated with nifedipine (1594 81 mgldl). Thus, the treatment of hemodialysis patients with nifedipine produced marked and significant improvement in the metabolic and functional parameters of B cells despite no changes in blood levels of PTH. These data indicate that the calcium channel blocker, nifedipine, interferes with PTH-induced rise in [Ca2]i of B cells of hemodialysis patients and consequently improves their metabolism and function. These observations if confirmed in other human cells may provide for a rational therapeutic approach to ameliorate the signs and symptoms of uremia.
0.31 X IO cpm vs. 9.8 0.38 x iO cpm) and smaller inhibition of B cell proliferation by PTH compared to those treated with nifedipine. The values in the patients treated with nifedipine were still modestly but significantly different than in normal subjects. The serum IgG levels of the patients without nifedipine therapy (1210 71 mg/dl) were significantly lower than those of the patients treated with nifedipine (1594 81 mgldl). Thus, the treatment of hemodialysis patients with nifedipine produced marked and significant improvement in the metabolic and functional parameters of B cells despite no changes in blood levels of PTH. These data indicate that the calcium channel blocker, nifedipine, interferes with PTH-induced rise in [Ca2]i of B cells of hemodialysis patients and consequently improves their metabolism and function. These observations if confirmed in other human cells may provide for a rational therapeutic approach to ameliorate the signs and symptoms of uremia.
Humoral immunity is impaired in patients with chronic renal failure. Indeed, the antibody response to viral antigen is reduced [1] , the number of total B cells may be decreased [2] [3] [4] , and both T cell-dependent and T-cell independent B cell proliferation are impaired [5] in these patients.
Alexiewicz et a! [6] reported that the proliferation of B cells I (SAC) or pokeweed mitogen was significantly lower than that observed with B cells from normal subjects. Further, antibody production (IgG, IgA and 1gM) by B cells in response to SAC and pokeweed mitogen was impaired in dialysis patients [7] . These derangements were attributed to the elevated blood levels of parathyroid hormone (PTH) in dialysis patients in that PTH produced similar derangements when applied to B cells from normal subjects [6, 7] .
PTH apparently exerts its deleterious effects on B cells by increasing their cytosolic calcium ([Ca2]i) and/or by stimulation of cAMP production by these cells. Indeed, [Ca2]i of B cells of dialysis patients is elevated [7] and the hormone augments cAMP production by these cells [6] . These effects are not surprising since B cells have receptors for PTH [8] [9] [10] .
It has been shown that calcium channel blockers reverse the elevation in [Ca2]i in polymorphonuclear leukocytes (PMNL), [11, 12] , normalize their abnormal carbohydrate metabolism [11] and significantly improve their phagocytic property [12] . It is, therefore, possible to propose that calcium channel blockers may also exert beneficial effect on B cell function.
The present study examined whether treatment of dialysis patients with nifedipine restores basal levels of [Ca2]i of B cells, their proliferation in response to SAC mitogen and their response to PTH to normal.
Methods
At the time of the study our dialysis unit had 68 patients. All nondiabetic dialysis patients treated with nifedipine (11 patients) and an additional 12 nondiabetic patients who were not being treated with nifedipine agreed to participate in the study. We also had 11 healthy subjects to serve as controls. Table I provides the characteristics and the biochemical parameters of the normal subjects and of the two groups of patients studied. None of the patients had evidence of systemic disease nor were they receiving medications known to affect the immune response. There were no significant differences between the various parameters among the two groups of dialysis patients. The cause of renal failure in the patients without nifedipine therapy was hypertension in 5, obstructive uropathy in 2, polycystic kidney disease in 1 and unknown in 4. In those treated with nifedipine, the renal failure was due to hypertension in 8, polycystic kidney disease in I and unknown cause in 2. The patients were dialyzed with cellulose acetate membrane (CA 210; Baxter Health Care Corp, Deerfield, IL, USA) three times per week for three hours each session. The Labs, NY, USA) and was given once daily. The relationship between the ingestion of medication, the blood sampling and dialysis procedure varied and was influenced by the timing of the dialysis procedure: in six patients nifedipine was taken at 10:00 a.m. and after the dialysis procedure; in these patients the blood samples were obtained between 5:00 and 5:30 a.m. In the other 5 patients the drug was ingested between 8:00 and 9:00 a.m. and before the dialysis procedure; in these patients the blood samples were obtained between 8:30 and 9:00 a.m. Blood samples were obtained under sterile conditions before the dialysis session and placed in vacutainers containing 20 U of preservative free heparin (Gibco Laboratories, Grand Island, NY, USA) per each 1.0 ml of blood.
Separation of B cells
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-hypaque centrifugation as described before [6] . B cells were separated from PBMC using rosetting with immunomagnetic 
Assay of B cell proliferation
The proliferation assay was made as described by Shenker and Matt [15] . Lymphocytes were cultured for five days in flatbottomed 96-well microplates (Linbro/Titertek; Flow Laboratories, McLean, VA, USA) in a humidified environment of 37°C and 5% CO2 in a water-jacket incubator (Forma Scientific, Marrietta, OH, USA). Each well contained 2 x io cells added to 100 pA of culture medium, and 100 pJ of SAC. In parallel, similar cultures of B cells were performed in the presence of 50 p1 of PTH delivering 1, 2 or 4 x i0 M PTH- . In cultures without PTH or mitogen, the desired amount of medium was added to reach the final volume of 250 j.rl. Cell proliferation was measured by the incorporation of [3H]thymidine (methyl-[3H]thymidine, specific activity 6.7 Ci/mmol; ICN Radiochemical, Irvine, CA, USA), which was added in the amount of 0.5 .tCi per well in 20 pJ of medium for the last four hours of culture. The cultures were then harvested onto glass-fiber filter paper by using an automatic cell harvester (Cambridge Technology Inc., Cambridge, MA, USA).
The filters were placed in scintillation vials, air dried, and quenched in Ecolite (JCN, Radiochemicals) before being counted in a liquid scintillation counter (Model LS 7000; Beckman Instruments, Palo Alto, CA) for the measurement of cell-bound radioactivity. Each study was performed in three to four replicates, and each well of these replicates was counted for three minutes. The result of each study is the mean cpm of the three to four replicates.
Assay of ATP in PBMC
The yield of pure B cells from each patients was not adequate to measure both [Ca2]i and ATP content. We therefore measured ATP in PBMC, which represents both T and B cells. The ATP content was measured according to the method reported by Lundin et al [16] . An aliquot of 0.5 ml of 0. of 50 al were assayed for ATP by the firefly luminescence assay with LAD 535 luminometer (Turner Design, Sunnyvale, CA, USA). ATP standards were prepared with 40 mM Tris buffer, distilled water and similar amounts of RPMI, perchloric acid, and K2C03 as in PBMC preparation.
Biochemical measurements
The concentration of calcium in plasma was measured with a Perkin Elmer spectrophotometer, and phosphorous and creatinine were estimated with an autoanalyzer (Technicon, Tarrytown, NY, USA). Serum levels of PTH were determined using radioisotopic assay (Intact PTH; Nichols Institute Diagnostic, San Juan, Capistrano, CA, USA; normal, 10 to 65 pglml). Serum levels of IgG were measured in 9 patients treated with nifedipine and in 11 patients without nifedipine therapy using the standard laboratory techniques.
Reagents
Staphylococcus aureus Cowan I. SAC was obtained from Bethesda Research Laboratories Inc. (Gaithersburg, MD, USA). It was prepared by diluting whole formalinized bacteria with culture media and was used in a final concentration of 1:50,000 vol/vol, which was established as optimal for our culture.
PTH. PTH- was purchased from Sigma. It was dissolved in 100 m acetic acid and diluted with culture media to obtain the desired concentration of I X iO, 2 X iO, and 4 X i0 M. The solution was filtered for sterility through 0.22 jsm-pore-size acetate membrane filters (Corning Glass Works, Corning, NY, USA) and was used within one day. 
Results
The repeated measurements of [Ca2]i in the same subjects showed excellent correlation between two measurements separated by 13 0.76 (9 to 17) months (Fig. 1) . The basal concentrations of {Ca2]i in B cells from dialysis patients without nifedipine therapy (120 1.9 nM) were significantly (P < 0.01) higher than those observed in B cells from normal subjects ( Fig. 2 ; 80 1.9 nM). This difference represents a value of 50% above normal. In the dialysis patients treated with nifedipine, the basal levels of {Ca2Ji of B cells were 94 2.2 flM, a value significantly lower than in patients without nifedipine therapy but still higher (P < 0.01) than normal levels by about 18%. This latter value is significantly (P < 0.05) higher than that in dialysis patients without nifedipine therapy but lower than those in normal subjects (P < 0.01). SAC mitogen induced significant (P < 0.01) increments in B cell proliferation in normal subjects and in both groups of dialysis patients (Fig. 4) . However, the increment in the dialysis patients without nifedipine therapy (from 1.2 0.14 X iO to 5.8 0.31 X iO cpm) was significantly (P < 0.01) smaller than in normal subjects (from 1.8 0.19 x lO to 12.5 0.55 X iO cpm). The treatment of dialysis patients with nifedipine was associated with a significant improvement in B cell proliferation in response to SAC (1.4 0.8 x iO to 9.8 0.34 x iO cpm). This change was significantly (P < 0.01) higher than in the dialysis patients without nifedipine but still lower (P < 0.05) than in normal subjects. All concentrations of PTH produced significant inhibition of B cell proliferation in normal subjects and in both groups of dialysis patients (Fig. 5) . However, the magnitude of the inhibition (% inhibition) was greater (P < 0,01) in normal subjects than in dialysis patients (Figs. 4 and 5) . The inhibition by PTH of the proliferation of B cells from dialysis patients without nifedipinc therapy was smaller (P < 0.05) than that noted in dialysis patients treated with nifedipine.
The serum concentrations of IgG in the dialysis patients without nifedipine therapy (1210 71 mgldl) were significantly (P < 0.01) lower than those in patients treated with nifedipine normal subjects and in patients treated with nifedipine than in patients without nifedipine therapy (**P 1 0.01) versus HD).
Discussion
The results of the present study demonstrate that the abnormalities in B cell metabolism and function previously reported in dialysis patients [6] are significantly ameliorated by the long-term treatment of these patients with nifedipine. Indeed, this agent restored toward normal the basal levels of [Ca2 ]i of B cells and their proliferation in response to mitogen and resulted in a rise in ATP content of PBMC as well. The improvement in B cell proliferation was also associated with higher levels of serum IgG. These observations are similar to those reported in regard to the metabolism and function of PMNL of dialysis patients [11, 12] . Indeed, Hon et al [11] showed that treatment of dialysis patients with verapamil reversed the abnormalities in their [Ca2]i and carbohydrate metabolism, and Alexiewicz et al [12] The improvements in B cell metabolism and function by nifedipine were not due to differences in Kt/V, duration of dialysis, hematocrit levels, treatment with 1,25(OH)2D3 or blood levels of PTH. It is more likely that the effect of nifedipine is A large body of evidence has accumulated indicating that the elevation in basal levels of [Ca2]i of many cells from rats with experimental chronic renal failure is responsible in major part for the dysfunction of these cells [18] . In these studies, the normal- The above-mentioned discussion may imply that the PTHmediated rise in [Ca2]i of B cells is the single cause responsible for B cell dysfunction in uremia. We emphasize that we do not claim that this is indeed the case. We believe that other consequences of uremia may also be operative.
Both in animals [18, 25] and in humans [6, 12] with chronic renal failure is the ATP content of many cells reduced. This phenomenon is also a consequence of the elevation in basal levels of [Ca2]i [18] . The present study showed that ATP content of another cell, PBMC, from dialysis patients is also reduced and these values were restored toward normal by nifedipine therapy. Although we did not measure the level of [Ca2Ii of PBMC, one may assume that they are elevated since the [Ca2]i of both B cells, as shown in the present study, arid of T cells [26] of hemodialysis patients are elevated. ATP measures cell energy state, and decreased ATP content of PBMC would reflect reduced availability of energy in both T and B cells. Under such circumstance, B cell proliferation could be impaired.
We have previously shown that PTH inhibited in a dose nifcdipine would increase the mRNA of the receptor, and improve the response to PTH. Dialysis patients have increased susceptility to infection [17, 18] . The United State Renal Data System showed that mortality due to infection among dialysis patients aged 45 to 64 years is 16%. Both B cells and PMNL are critical for the defense of the body against infection, and the beneficial effect of calcium channel blockers on the metabolism and function of these cells could provide a useful tool in the fight against infection in these patients.
